These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 7862918)
1. Transdermal nicotine: reduction of smoking with minimal abuse liability. Pickworth WB; Bunker EB; Henningfield JE Psychopharmacology (Berl); 1994 Jun; 115(1-2):9-14. PubMed ID: 7862918 [TBL] [Abstract][Full Text] [Related]
2. Effect of transdermal nicotine patches on cigarette smoking: a double blind crossover study. Foulds J; Stapleton J; Feyerabend C; Vesey C; Jarvis M; Russell MA Psychopharmacology (Berl); 1992; 106(3):421-7. PubMed ID: 1570391 [TBL] [Abstract][Full Text] [Related]
3. Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal. Teneggi V; Tiffany ST; Squassante L; Milleri S; Ziviani L; Bye A Psychopharmacology (Berl); 2002 Nov; 164(2):177-87. PubMed ID: 12404080 [TBL] [Abstract][Full Text] [Related]
4. Effects of transdermal nicotine delivery on measures of acute nicotine withdrawal. Pickworth WB; Fant RV; Butschky MF; Henningfield JE J Pharmacol Exp Ther; 1996 Nov; 279(2):450-6. PubMed ID: 8930145 [TBL] [Abstract][Full Text] [Related]
5. Effect of transdermal nicotine replacement on alcohol responses and alcohol self-administration. McKee SA; O'Malley SS; Shi J; Mase T; Krishnan-Sarin S Psychopharmacology (Berl); 2008 Feb; 196(2):189-200. PubMed ID: 17912500 [TBL] [Abstract][Full Text] [Related]
6. Nicotine patches and the subjective effects of cigarette smoking: a pilot study. Cárdenas L; Busto UE; MacDonald A; Corrigall WA Can J Clin Pharmacol; 2002; 9(4):175-82. PubMed ID: 12584575 [TBL] [Abstract][Full Text] [Related]
7. Transdermal nicotine maintenance attenuates the subjective and reinforcing effects of intravenous nicotine, but not cocaine or caffeine, in cigarette-smoking stimulant abusers. Sobel BF; Sigmon SC; Griffiths RR Neuropsychopharmacology; 2004 May; 29(5):991-1003. PubMed ID: 15010695 [TBL] [Abstract][Full Text] [Related]
8. Nicotine-replacement therapy with use of a transdermal nicotine patch--a randomized double-blind placebo-controlled trial. Hurt RD; Lauger GG; Offord KP; Kottke TE; Dale LC Mayo Clin Proc; 1990 Dec; 65(12):1529-37. PubMed ID: 2255215 [TBL] [Abstract][Full Text] [Related]
10. Effects of varenicline versus transdermal nicotine replacement therapy on cigarette demand on quit day in individuals with substance use disorders. Murphy CM; MacKillop J; Martin RA; Tidey JW; Colby SM; Rohsenow DJ Psychopharmacology (Berl); 2017 Aug; 234(16):2443-2452. PubMed ID: 28500373 [TBL] [Abstract][Full Text] [Related]
13. Varying nicotine patch dose and type of smoking cessation counseling. Jorenby DE; Smith SS; Fiore MC; Hurt RD; Offord KP; Croghan IT; Hays JT; Lewis SF; Baker TB JAMA; 1995 Nov; 274(17):1347-52. PubMed ID: 7563558 [TBL] [Abstract][Full Text] [Related]
14. Effects of high dose transdermal nicotine replacement in cigarette smokers. Hatsukami D; Mooney M; Murphy S; LeSage M; Babb D; Hecht S Pharmacol Biochem Behav; 2007 Jan; 86(1):132-9. PubMed ID: 17267026 [TBL] [Abstract][Full Text] [Related]
15. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Dalack GW; Becks L; Hill E; Pomerleau OF; Meador-Woodruff JH Neuropsychopharmacology; 1999 Aug; 21(2):195-202. PubMed ID: 10432467 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers. DeVeaugh-Geiss AM; Chen LH; Kotler ML; Ramsay LR; Durcan MJ Clin Ther; 2010 Jun; 32(6):1140-8. PubMed ID: 20637967 [TBL] [Abstract][Full Text] [Related]
17. Smoking Topography Characteristics of Very Low Nicotine Content Cigarettes, With and Without Nicotine Replacement, in Smokers With Schizophrenia and Controls. Tidey JW; Cassidy RN; Miller ME Nicotine Tob Res; 2016 Sep; 18(9):1807-12. PubMed ID: 26995794 [TBL] [Abstract][Full Text] [Related]
18. Prediction of abstinence at 10 weeks based on smoking status at 2 weeks during a quit attempt: secondary analysis of two parallel, 10-week, randomized, double-blind, placebo-controlled clinical trials of 21-mg nicotine patch in adult smokers. Ferguson SG; Gitchell JG; Shiffman S; Sembower MA Clin Ther; 2009 Sep; 31(9):1957-65. PubMed ID: 19843485 [TBL] [Abstract][Full Text] [Related]
19. Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking. Rose JE; Behm FM; Westman EC Pharmacol Biochem Behav; 2001 Feb; 68(2):187-97. PubMed ID: 11267622 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Sachs DP; Säwe U; Leischow SJ Arch Intern Med; 1993 Aug; 153(16):1881-90. PubMed ID: 8110249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]